NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
This article was originally published in The Tan Sheet
Executive Summary
NRT firms' reliance on "unpublished, ad hoc" FDA statements to support their contention that a Proposition 65 warning on OTC smoking cessation products conflicts with federal law is improper, according to a brief filed in California Supreme Court April 15